Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Free Cash Flow (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Free Cash Flow for 16 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 415.96% to -$6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.8 million through Dec 2025, down 94.79% year-over-year, with the annual reading at -$20.8 million for FY2025, 94.79% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$6.3 million at Plus Therapeutics, down from -$2.6 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$1.2 million in Q4 2024, with the low at -$6.3 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$3.6 million, with a median of -$3.1 million recorded in 2021.
  • The sharpest move saw Free Cash Flow skyrocketed 55.86% in 2024, then plummeted 415.96% in 2025.
  • Over 5 years, Free Cash Flow stood at -$3.1 million in 2021, then increased by 23.56% to -$2.4 million in 2022, then increased by 18.59% to -$1.9 million in 2023, then surged by 36.45% to -$1.2 million in 2024, then tumbled by 415.96% to -$6.3 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$6.3 million, -$2.6 million, and -$5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.